AUPH Aurinia Corp: Net earnings per share for the last 12 months

The year-over-year EPS (TTM) comparison for Aurinia Pharmaceuticals (AUPH) demonstrates earnings per share dynamics, highlighting high data transparency and the management's scientific approach. Peter Greenleaf is focusing on scaling sales of the core drug and reducing costs. Stable partner capacities fully cover the demand for immune therapies. The value of 312.00 describes the current level of business efficiency without time lags.
Aurinia Corp - analytical breakdowns and key metrics (AUPH)

The exclusivity of its lupus nephritis therapy allows Aurinia Pharmaceuticals (AUPH) to maintain high drug pricing, directly impacting the business's bottom-line profitability. The earnings per share trend over the last twelve months compared to the previous period, as reflected in the 12-month EPS YoY history on GURU.Markets, demonstrates the effectiveness of monetizing this advantage and confirms the company's fundamental stability.